Epimune’s goal is to revolutionize diagnosis and monitoring of patients with disorders of the immune system
Using epigenetics, Epimune develops & commercializes molecular diagnostic tests for immune cell quantification from a drop of blood
For a Spanish version of this video please click here!
Berlin, 08 July 2020 - Epimune today completed CE-marking of its first in vitro diagnostic (IVD) test, the i.Mune TBNK Test, with the signing of the declaration of conformity and registration with the German Institute for Medical Documentation and Information (DIMDI). This is another milestone in the short history of our company, which started operations in April 2019.